research use only
Cat.No.S8502
|
In vitro |
DMSO
: 91 mg/mL
(199.37 mM)
Ethanol : 91 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 456.42 | Formula | C23H19F3N4O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1314891-22-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | TFMO 2 | Smiles | CC(C)(CNC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C(F)(F)F)C3=COC(=N3)C4=CC=CC=C4 | ||
| Targets/IC50/Ki |
HDAC9
(Cell-free assay) 15 nM(Ki)
HDAC7
(Cell-free assay) 26 nM(Ki)
HDAC4
(Cell-free assay) 59 nM(Ki)
HDAC5
(Cell-free assay) 60 nM(Ki)
|
|---|---|
| In vitro |
TMP195 has low potency in recombinant class I and IIb HDAC assays, enabling full inhibition of class IIa HDAC activity without inhibition of other HDACs. This compound blocks the accumulation of CCL2 protein in the supernatants of monocyte-derived macrophage differentiation cultures and significantly increases the amount of CCL1 protein secreted by the monocytes compared to vehicle (DMSO)-treated M-CSF plus GM-CSF cultures. It influences human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro. |
| In vivo |
In vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. This compound induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours. Its treatment significantly decreases proliferating tumour cells, most notably at the leading edge of the tumour. The anti-tumour macrophage phenotype induced by this chemical thus enhances the efficacy and durability of both standard chemotherapeutic regimens and checkpoint blockade immunotherapy in this mouse model of breast cancer. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.